Genetic deletion of Ezh2 in donor T cells or pharmacologic inhibition of EZH2 has been shown to prevent GvHD without affecting the GvL effect in mouse models of allo-HSCT [148,149]. The gene discussed is EZH2; the disease is graft versus host disease.